Description

NICARDIA RETARD 10 MG

Indications

Nicardia Retard 10 mg, which contains the active ingredient nicardipine, is primarily indicated for the management of hypertension (high blood pressure) and the treatment of angina pectoris (chest pain). It is particularly beneficial for patients who may not respond adequately to other antihypertensive agents. The extended-release formulation allows for once-daily dosing, improving patient adherence to treatment regimens.

Mechanism of Action

Nicardipine is a calcium channel blocker that primarily affects the L-type calcium channels in vascular smooth muscle and cardiac muscle. By inhibiting calcium influx during depolarization, nicardipine causes relaxation of vascular smooth muscle, leading to vasodilation. This results in a decrease in systemic vascular resistance and arterial blood pressure. Additionally, by reducing calcium entry into cardiac muscle cells, nicardipine can decrease myocardial oxygen demand, making it effective in the treatment of angina.

Pharmacological Properties

Nicardipine exhibits a rapid onset of action, with peak plasma concentrations typically occurring within 1 to 2 hours after oral administration. The bioavailability of nicardipine is approximately 30%, and it undergoes extensive first-pass metabolism in the liver. The half-life of nicardipine is about 8 to 10 hours, allowing for once-daily dosing in its extended-release form. The drug is primarily excreted in the urine, with less than 1% of the dose excreted unchanged.

Contraindications

Nicardia Retard 10 mg is contraindicated in patients with known hypersensitivity to nicardipine or any of its components. It should not be used in patients with severe aortic stenosis, as the drug may exacerbate the condition. Additionally, it is contraindicated in patients who are pregnant or breastfeeding unless the potential benefits outweigh the risks, as there is limited data on its safety in these populations.

Side Effects

Common side effects associated with Nicardia Retard 10 mg include headache, flushing, dizziness, and peripheral edema. Other less common side effects may include palpitations, nausea, and fatigue. Serious adverse effects, although rare, can include hypotension, tachycardia, and allergic reactions. Patients should be monitored for any unusual symptoms, and if severe side effects occur, medical attention should be sought immediately.

Dosage and Administration

The recommended starting dose of Nicardia Retard is 10 mg once daily, which may be adjusted based on the patient’s response and tolerability. The maximum recommended dose is 30 mg per day, administered as 10 mg three times daily. It is advisable to take the medication at the same time each day to maintain consistent blood levels. The tablet should be swallowed whole and not crushed or chewed to ensure the extended-release formulation functions properly.

Interactions

Nicardia Retard may interact with several medications, which can either enhance its effects or increase the risk of side effects. Co-administration with other antihypertensive agents may lead to additive hypotensive effects. Caution should be exercised when using nicardipine with CYP3A4 inhibitors (such as ketoconazole or erythromycin), as these can increase nicardipine levels and enhance its effects. Conversely, CYP3A4 inducers (such as rifampicin) may decrease the effectiveness of nicardipine. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Patients with a history of heart failure, hepatic impairment, or renal impairment should use Nicardia Retard with caution. Regular monitoring of blood pressure and heart rate is recommended, especially during the initiation of therapy or when adjusting the dose. It is important to assess the patient’s overall cardiovascular status before starting treatment. Patients should also be advised to avoid sudden discontinuation of the medication, as this may lead to rebound hypertension.

Clinical Studies

Clinical studies have demonstrated the efficacy of Nicardia Retard in reducing blood pressure and improving exercise tolerance in patients with angina. In a randomized controlled trial, patients treated with nicardipine showed significant reductions in both systolic and diastolic blood pressure compared to placebo. Additionally, patients reported fewer episodes of angina and improved quality of life. Long-term studies have indicated that nicardipine is effective in maintaining blood pressure control over extended periods, with a favorable safety profile.

Conclusion

Nicardia Retard 10 mg is an effective option for the management of hypertension and angina pectoris. Its unique mechanism of action as a calcium channel blocker allows for significant cardiovascular benefits, including vasodilation and reduced myocardial oxygen demand. While generally well-tolerated, it is important for patients to be aware of potential side effects and drug interactions. Regular monitoring and communication with healthcare providers can help ensure optimal treatment outcomes.